DSM acquires Microbia
This article was originally published in The Tan Sheet
Executive SummaryRoyal DSM will expand its natural carotenoids business by incorporating Microbia's proprietary platform and research and development capabilities. The Netherlands chemicals giant acquired Lexington, Mass.-based Microbia from Ironwood Pharmaceuticals under undisclosed terms, according to a Sept. 22 release. Microbia developed a technology platform that enables the production of natural carotenoids - including carotene and canthaxanthin - nutritional products and other specialty materials and chemicals from renewable resources
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.